Univo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Univo Pharmaceuticals has a total shareholder equity of ₪20.5M and total debt of ₪39.6M, which brings its debt-to-equity ratio to 193.1%. Its total assets and total liabilities are ₪75.9M and ₪55.4M respectively.
Key information
193.1%
Debt to equity ratio
₪39.60m
Debt
| Interest coverage ratio | n/a |
| Cash | ₪4.50m |
| Equity | ₪20.50m |
| Total liabilities | ₪55.44m |
| Total assets | ₪75.94m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: UNVO's short term assets (₪34.3M) exceed its short term liabilities (₪25.8M).
Long Term Liabilities: UNVO's short term assets (₪34.3M) exceed its long term liabilities (₪29.7M).
Debt to Equity History and Analysis
Debt Level: UNVO's net debt to equity ratio (171.2%) is considered high.
Reducing Debt: Insufficient data to determine if UNVO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UNVO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: UNVO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.5% each year